FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 171 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... February 8, 2022 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes July 14, 2020 A career forged in team science March 10, 2023 Load more HOT NEWS FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia EMA Recommends Extension of Therapeutic Indications for Olaparib Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological...
